What are the specifications, indications, efficacy and functions of budesonide sustained-release capsules?

Budesonide sustained-release capsules are available in two specifications, and different specifications treat different diseases. Budesonide sustained-release capsule is a locally acting glucocorticoid drug, and its main component budesonide has significant anti-inflammatory effects. It is mainly used to treat inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, as well as autoimmune hepatitis, nephritis and other inflammatory diseases.

Specifications of budesonide sustained-release capsules

1. Sustained-release capsules: 4mg*120 capsules.

2. Sustained-release capsules: 3mg*100 capsules.

Indications

1. Budesonide Sustained-Release Capsules 3mg: Mild to moderately active Crohn's disease in patients 8 years old and above.

2. Budesonide extended-release capsules 4 mg: reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.

Effects and effects

1. Reduce intestinal inflammation: For patients with Crohn's disease and ulcerative colitis, budesonide sustained-release capsules can reduce intestinal inflammation and improve intestinal symptoms such as abdominal pain, diarrhea and bloody stools.

2. Control the progression of the disease: For inflammatory diseases such as autoimmune hepatitis and nephritis, budesonide sustained-release capsules can help control the development of the disease and reduce disease activity.

3. Reduce immune response: Budesonide can inhibit the excessive response of the immune system, reduce the release of inflammatory mediators, thereby reducing tissue damage.

4. Improve quality of life: By reducing inflammatory symptoms and related complications, budesonide sustained-release capsules help improve patients' quality of life.

Different specifications of budesonide sustained-release capsules

1. 3mg

1. Export Turkish version of budesonide sustained-release capsules: the reference price for a box of 3mg*100 capsules is about 1,380$.

2. German version of budesonide sustained-release capsules: the reference price for a box of 3mg*100 capsules is about 1,950$.

2. 4mg

The reference price of budesonide sustained-release capsules from Germany's Stade Group: 4mg*120 capsules per box is about $81,650, which is more expensive.

Usage and Dosage

1. Budesonide sustained-release capsules 3 mg

1. Adults and adolescents 12 years old and above: The initial dose is 9 mg, which is equivalent to taking three 3 mg capsules, once a day. After taking it for 7 days, the dose is reduced to 6 mg, which is two 3 mg capsules, once a day.

2. Patients weighing more than 70 kg: The initial dose is 12mg, which is equivalent to taking 4 3mg capsules, once a day. After taking it for 7 days, the dose is reduced to 9mg, which is 3 3mg capsules, once a day.

2. Budesonide sustained-release capsules 4 mg

The recommended dose is 16 mg, taken orally once a day, which is equivalent to taking four 4 mg capsules a day. The recommended duration of treatment is 9 months, with the dosage reduced to 8 mg during the last 2 weeks of treatment, i.e. two 4 mg capsules, once daily.

Budesonide sustained-release capsules for the treatment of kidney disease

Immunoglobulin A nephropathy is a common autoimmune kidney disease. More and more studies have shown that IgA nephropathy may be partially related to mucosal immune system dysfunction. Systemic corticosteroid therapy has an important protective effect against renal exacerbation of IgA nephropathy. However, long-term use of corticosteroids may cause systemic side effects. A novel targeted release formulation (TRF) of budesonide has been shown to deliver the drug to the terminal ileum with the aim of minimizing adverse events in patients with IgA nephropathy.

In a comprehensive review of three randomized controlled trials (RCTs), one cohort, two case reports and one ongoing phase 3 trial. These studies show that budesonide sustained-release capsules can significantly reduce proteinuria, hematuria, and creatinine and protect renal function. The local immunosuppressive effect of budesonide sustained-release capsules may be a new promising method for the treatment of IgA nephropathy.

References:

Liao J, Zhou Y, Xu X, Huang K, Chen P, Wu Y, Jin B, Hu Q, Chen G, Zhao S. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. Front Immunol. 2023 Jan 4;13:926517. doi: 10.3389/fimmu.2022.926517. PMID: 36685528; PMCID: PMC9846030.

Related hot recommendations: Is American deuterated colexitinib effective?